Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, the author summarized activities from a six-month internship in community and hospital pharmacy settings, exploring topics like skin microbiome health implications and advancements in antiviral therapy for Hepatitis B and D, highlighting the pharmacist's role in patient care and innovative treatments.

This review discusses the symptoms, diagnosis, and current treatment recommendations for polycystic ovary syndrome, noting that many women may remain undiagnosed and at risk for complications.

This review discusses the onset of menstruation and related challenges in young women, with a focus on primary amenorrhea, its diagnosis, and management strategies, and reports no new clinical findings.

This review discusses the prevalence and management of polycystic ovary syndrome in women, particularly noting gaps in understanding its presence in adolescents, and reports no new clinical findings.

This review discusses the indications, contraindications, and potential for using hormonal therapy as a first-line treatment for acne in females, but reports no new clinical results.

This review discusses the perimenopause, its symptoms, and management options, emphasizing the role of pharmacists in educating and advising women on treatment strategies and preventive health measures, but it reports no new results.

Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This review summarizes current melasma treatments, emphasizing the need for tailored, long-term management strategies that integrate photoprotection and address various pathogenic mechanisms.

This case report documents a 20-year-old female runner with recurrent bone stress injuries, concluding they were due to low bone density from uncontrolled Celiac Disease and functional hypothalamic amenorrhea from low energy availability.

This review examines microneedle patches for drug delivery, detailing their designs, materials, manufacturing methods, and potential advantages, but reports no new clinical results.

This study reported that in animal studies of androgenetic alopecia, a biodegradable microneedle patch releasing glutamic acid promoted hair regeneration more effectively than daily minoxidil, with higher hair follicle counts and less frequent dosing, showing the potential for clinical application.

This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.

This review discusses the wide range of drugs potentially causing reversible or irreversible hair loss and emphasizes the difficulty of diagnosing drug-induced alopecia without withdrawal of the suspected medication; it reports no new clinical findings.

This review discusses the psychological and emotional effects of common dermatologic conditions and highlights their impact on quality of life, but it does not present new clinical results.

This review discusses neuroimmune communication in skin disorders and peripheral neuropathic pain, highlighting the complex interactions between sensory neurons and immune cells; it reports no new clinical results but suggests potential future therapies.

This review highlights recent advances in personalized transdermal drug delivery systems, noting their potential for improved treatment efficacy and safety, but identifies significant challenges in clinical translation.

This review discusses female pattern hair loss, highlighting that while oral antiandrogens and topical minoxidil can arrest progression, early diagnosis and treatment are crucial, and stresses the need for ongoing therapy.

This article discusses the impact of hyperandrogenism in polycystic ovary syndrome on women's physical and mental health, but it reports no new experimental findings.

This review discusses the roles of steroid hormone receptors in lung function related to COVID-19 and outlines ongoing clinical trials of steroid receptor ligands, but reports no new results.

This study found that acne, hirsutism, and other skin conditions are prevalent among Jordanian women with polycystic ovary syndrome, often linked to specific hormonal imbalances and higher BMI.

This review discusses the complexities and co-morbidities associated with polycystic ovary syndrome, including its impact on metabolic and psychological health, and reports no new clinical results.

This study found that the prevalence of polycystic ovarian syndrome among women of reproductive age in urban and rural areas of Hyderabad, Telangana, is between 6.5% and 6.8%.

In this descriptive cross-sectional study, researchers observed that cutaneous manifestations such as hirsutism, acne, and androgenic alopecia are common in women with PCOS, with obesity significantly worsening hirsutism, highlighting the importance of early dermatological assessment for PCOS diagnosis and management.

This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.

This study observed that women using combined oral contraceptives experienced more nausea, vomiting, and hair loss, while those on Depo-Provera were more likely to gain weight.

This update discusses guidelines for dermatology nurses and nurse practitioners on polycystic ovary syndrome but presents no new research findings; it emphasizes their role in early diagnosis through recognizing skin symptoms.

This chapter reviews patchy hair loss due to skin disease, nail disorders related to chronic trauma, and treatments for small carcinomas, but it reports no new clinical findings.

This study reports that non-surgical treatments like triamcinolone acetonide and Botulinum toxin Type A reduced keloid volume by up to 80% in children, with combination therapies being safer and having fewer side effects.

This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.